Goldenwell Biotech (GWLL) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 30, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the GWLL SEC filings page.
Goldenwell Biotech Inc (GWLL) reported $55 in revenue over the twelve months to Jun 30, 2026. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
We do not publish a peer-relative financial health score for Goldenwell Biotech Inc, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Goldenwell Biotech Inc reported an operating loss of $113K against $8K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Goldenwell Biotech Inc generated $0 in revenue in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Goldenwell Biotech Inc reported a net loss of $37K in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Goldenwell Biotech Inc earned $0.00 per diluted share (EPS) in Q2 2026. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q2 2026.
Cash & Balance Sheet
Goldenwell Biotech Inc held $11K in cash as of Q2 2026; no long-term debt figure is on record for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
None of these metrics is reported for Q2 2026.
Capital Allocation
None of these metrics is reported for Q2 2026.
GWLL Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q/A |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0n/m | $0n/m | $55n/m | $0n/m | $0-100.0% | $0-100.0% | $0-100.0% | $0-100.0% |
| Cost of Revenue | $0n/m | $0n/m | $43n/m | $0n/m | $0-100.0% | $0n/m | $0-100.0% | $0-100.0% |
| Gross Profit | $0n/m | $0n/m | $12n/m | $0n/m | $0-100.0% | $0n/m | $0-100.0% | $0-100.0% |
| SG&A Expenses | $35K+23.3% | $31K-14.0% | $23K-9.6% | $26K+23.0% | $28K-41.1% | $36K+25.8% | $25K+21.5% | $21K-41.1% |
| Operating Income | -$35Kn/m | -$31Kn/m | -$23Kn/m | -$26Kn/m | -$28Kn/m | -$36Kn/m | -$25Kn/m | -$21Kn/m |
| Interest Expense | N/A | $2K0.0% | $2K0.0% | $2K0.0% | $2K0.0% | $2K0.0% | $2K | $2K |
| Income Tax | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0 | $0 |
| Net Income | -$37Kn/m | -$18Kn/m | N/A | -$28Kn/m | -$30Kn/m | -$39Kn/m | -$27Kn/m | -$23Kn/m |
| EPS (Diluted) | $0.00 | $0.00n/m | $0.00n/m | N/A | N/A | $0.00n/m | $0.00 | N/A |
| Diluted Shares (Avg) | 99M0.0% | 99M0.0% | 99M0.0% | 96M0.0% | 99M+2.7% | 99M0.0% | 99M | 96M |
Not reported in any period shown, so not listed: R&D Expenses, EBITDA, EPS (Basic).
GWLL Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q/A |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $29K-89.2% | $19K-90.2% | $36K-83.9% | $234K+30.3% | $267K+33.4% | $192K-3.5% | $224K-1.7% | $179K-4.0% |
| Cash & Equivalents | $11K-85.4% | $13K-21.7% | $27K-45.8% | $46K+859.5% | $77K+197.5% | $17K-29.3% | $49K-7.2% | $5K-60.1% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Inventory | $0-100.0% | $0-100.0% | N/A | $175K+0.1% | $175K+0.1% | $175K0.0% | $175K0.0% | $175K-0.2% |
| Accounts Receivable | N/A | $0n/m | N/A | $0n/m | $0n/m | $0n/m | $0n/m | $0 |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $427K+11.4% | $380K+36.9% | $380K+39.9% | $378K+90.1% | $383K+95.0% | $278K+91.2% | $271K+88.7% | $199K+144.0% |
| Current Liabilities | $100K-8.8% | $100K | $102K+5376.3% | $102K | $110K | N/A | $2K | N/A |
| Non-Current Liabilities | $327K+19.5% | $280K | $278K+3.1% | $276K | $274K | N/A | $270K | N/A |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | $176K | $174K+275.5% | N/A |
| Total Equity | -$398Kn/m | -$361Kn/m | -$344Kn/m | -$144Kn/m | -$116K-3554.7% | -$86K-261.0% | -$47K-156.1% | -$21K-119.8% |
| Retained Earnings | -$1.7Mn/m | -$1.7Mn/m | -$1.7Mn/m | -$1.5Mn/m | -$1.4Mn/m | -$1.4Mn/m | -$1.4Mn/m | -$1.3Mn/m |
Not reported in any period shown, so not listed: Current Assets, Goodwill.
GWLL Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
GWLL Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q/A |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | 21.8% | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | -41627.3% | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -127.3%-115.9pp | -93.9%-73.8pp | N/A | -11.9%+0.9pp | -11.3%+13.6pp | -20.1%-4.5pp | -12.2%-3.1pp | -12.8%+6.1pp |
| Asset Turnover | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x |
Not reported in any period shown, so not listed: Net Margin, Return on Equity, Current Ratio, Debt-to-Equity, Liabilities-to-Equity, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin.
Note: Shareholder equity is negative (-$344K), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Goldenwell Biotech Inc GWLL | FY2025 | $55 | N/A | N/A | $64.3M | — |
| UMeWorld Inc UMEW | FY2025 | $2K | -$258K | N/A | $98.7M | — |
| Harvard Apprats REG TCH HRGN | FY2025 | $704K | -$6.9M | N/A | $46.7M | — |
Where Goldenwell Biotech Inc Ranks
Frequently Asked Questions
Goldenwell Biotech Inc (GWLL) reported $55 in total revenue for fiscal year 2025. This represents a -60.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Goldenwell Biotech Inc (GWLL) revenue declined by 60.4% year-over-year, from $139 to $55 in fiscal year 2025.
Goldenwell Biotech Inc (GWLL) had a gross margin of 21.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
Goldenwell Biotech Inc (GWLL) recorded an outflow of $23K in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Goldenwell Biotech Inc (GWLL) had $36K in total assets as of fiscal year 2025, including both current and long-term assets.
Goldenwell Biotech Inc (GWLL) has no price-to-earnings ratio at the moment: no net income reported. The market capitalization is $64.3M as of Oct 30, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Goldenwell Biotech Inc (GWLL) has no price-to-sales ratio at the moment: outside the range published as a multiple (on $55 revenue, trailing 12 months to June 30, 2026). The market capitalization is $64.3M as of Oct 30, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2025, Goldenwell Biotech Inc (GWLL) held $27K in cash, cash equivalents and investments, and reported an operating cash outflow of $23K over that year. Dividing the one by the other, the reported balance equals about 14 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Goldenwell Biotech Inc (GWLL) has negative shareholder equity of -$344K as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
Goldenwell Biotech Inc (GWLL) reported an operating loss of $113K against $8K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.